|
3.3 PRÉVENTION - VACCINS
|
|
|
HPV vaccine for boys raises hope of eradicating cervical cancer [The Telegraph]
|
|
|
|
|
|
Professor Beate Kampmann, director of the vaccine centre at the London School of Hygiene and Tropical Medicine, said: "This decision is a triumph for gender equality in cancer prevention. "It's pleasing to see the UK follow the example of other countries like Australia, where the vaccine has been implemented for girls since 2007 and for boys since 2013."
|
|
|
|
|
|
|
|
HPV vaccine for boys 'will prevent thousands of cancers' [BBC News]
|
|
|
|
|
|
Boys who are 14 to 18 will not be able to get a free, catch-up vaccine in the UK - but they can buy it for around £150 per dose. Health officials say that boys are already benefitting from protection from the girls' HPV vaccination programme and this has reduced the spread of the virus.
|
|
|
|
|
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
Blood test could predict breast cancer relapse [City of Hope]
|
|
|
|
|
|
Lee and his colleagues used data on 40 breast cancer patients who were followed for a median of four years. Results were validated in a separate cohort of 38 additional breast cancer patients to create a benchmark that predicts if a breast cancer patient will likely relapse within a handful of years.
|
|
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
Array’s colorectal cancer data shows why Pfizer splashed out $11B for the biotech [Fierce Pharma]
|
|
|
|
|
|
A combination of Array’s BRAF inhibitor Braftovi, its MEK inhibitor Mektovi and the anti-EGFR drug Erbitux significantly extended lives of previously-treated patients with certain BRAF-mutant metastatic colorectal cancer (mCRC) to a median of 9 months, versus 5.4 months in those who received Erbitux and chemo. But the key question for Pfizer's future sales is whether both Array drugs are needed to reach that kind of result. Would just one do?
|
|
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
|
|
|
|
6.11 PATIENTS
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
|
|
|